Back to Awarded Treatment Trials
Awarded Trial: 04T-584
Grant ID
04T-584
Illness
Schizophrenia with Metabolic Abnormalities
Primary Drug/Intervention
Pioglitazone
Primary Dosage
30 mg
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Smith
Sample Size
40
Duration of Study Period for Each Subject
12 weeks
Outcome Measurements
Body mass index and related measures; glucose, lipids and related measures; PANSS, CGI, cognitive battery
Results
Fifty-four (54) patients with schizophrenia were randomized to adjunct pioglitazone or placebo for 12 weeks. The study was done at five sites in the U.S. and one in China. Patients on pioglitazone showed a significant improvement on the PANSS total score as well as improvement in some metabolic indicators, as expected. Pioglitzaone had no effect on cognition. Analysis of the data was complicated by the fact that results in the Chinese population differed somewhat that at the five U.S. sites.
Publication
Smith RC, Jin H, Li C, Bark N, Shekhar A, Dwivedi S, et al. Effects of Pioglitazone on Metabolic Abnormalities, Psychopathology, and Cognitive Function in Schizophrenic Patients Treated with Antipsychotic Medication: A Randomized Double-Blind Study. Shizophr Res 2013;143:18-24.
Link
N/A
PI Name
Robert Smith
Degree
MD
Center
Department of Psychiatry
Institution
NYU Medical School
Address
P.O. Box 316
City or Town
Hewlett
State or Province
NY
Zip or Postal Code
11557
Country
USA
Email Address
robert.smith@med.nyu.edu